Cargando…
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978321/ https://www.ncbi.nlm.nih.gov/pubmed/31974371 http://dx.doi.org/10.1038/s41408-020-0274-9 |
| _version_ | 1783490672960995328 |
|---|---|
| author | Wang, D. Zeng, C. Xu, B. Xu, J.-H. Wang, J. Jiang, L.-J. Wang, Q.-X. Li, C.-R. Wang, N. Huang, L. Zhang, Y.-C. Xiao, Y. Zhou, J.-F. |
| author_facet | Wang, D. Zeng, C. Xu, B. Xu, J.-H. Wang, J. Jiang, L.-J. Wang, Q.-X. Li, C.-R. Wang, N. Huang, L. Zhang, Y.-C. Xiao, Y. Zhou, J.-F. |
| author_sort | Wang, D. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6978321 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69783212020-01-28 Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients Wang, D. Zeng, C. Xu, B. Xu, J.-H. Wang, J. Jiang, L.-J. Wang, Q.-X. Li, C.-R. Wang, N. Huang, L. Zhang, Y.-C. Xiao, Y. Zhou, J.-F. Blood Cancer J Correspondence Nature Publishing Group UK 2020-01-23 /pmc/articles/PMC6978321/ /pubmed/31974371 http://dx.doi.org/10.1038/s41408-020-0274-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Wang, D. Zeng, C. Xu, B. Xu, J.-H. Wang, J. Jiang, L.-J. Wang, Q.-X. Li, C.-R. Wang, N. Huang, L. Zhang, Y.-C. Xiao, Y. Zhou, J.-F. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients |
| title | Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients |
| title_full | Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients |
| title_fullStr | Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients |
| title_full_unstemmed | Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients |
| title_short | Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients |
| title_sort | anti-cd30 chimeric antigen receptor t cell therapy for relapsed/refractory cd30(+) lymphoma patients |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978321/ https://www.ncbi.nlm.nih.gov/pubmed/31974371 http://dx.doi.org/10.1038/s41408-020-0274-9 |
| work_keys_str_mv | AT wangd anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT zengc anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT xub anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT xujh anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT wangj anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT jianglj anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT wangqx anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT licr anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT wangn anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT huangl anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT zhangyc anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT xiaoy anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients AT zhoujf anticd30chimericantigenreceptortcelltherapyforrelapsedrefractorycd30lymphomapatients |